Who Owns Monopar Therapeutics Stock?
NASDAQ: MNPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 91.95%
- Institutions (% of float)
- 119.80%
- Held by insiders
- 23.24%
- Institutional holders
- 139
- Institutions 76.8%
- Insiders 23.2%
- Public and other 0.0%
Who owns Monopar Therapeutics stock?
Institutional investors own about 92.0% of Monopar Therapeutics's shares, spread across 139 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 23.24% of MNPR.
The largest institutional holders are Janus Henderson Group Ltd. (16.52%), RA Capital Management, L.P. (9.85%) and Blackrock Inc. (5.15%). Together, the top 10 institutions control 56.0% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their MNPR positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of MNPR
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Janus Henderson Group Ltd. | 1.12M | 16.52% | -15.0% |
| RA Capital Management, L.P. | 667.21K | 9.85% | 0.0% |
| Blackrock Inc. | 349.24K | 5.15% | +0.1% |
| Saturn V Capital Management LP | 312.35K | 4.61% | +0.1% |
| Siren, L.L.C. | 270.12K | 3.99% | 0.0% |
| State Street Corporation | 229.77K | 3.39% | +148.3% |
| Vanguard Capital Management LLC | 217.96K | 3.22% | +3.9% |
| Polar Capital Holdings PLC | 213.81K | 3.16% | -0.3% |
| Adage Capital Partners GP L.L.C. | 209.19K | 3.09% | 0.0% |
| TCG Crossover Management, LLC | 202.24K | 2.98% | -0.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of MNPR
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 159.79K | 2.36% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 137.26K | 2.03% |
| iShares Trust-iShares Russell 2000 ETF | 119.52K | 1.76% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 49.33K | 0.73% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 44.31K | 0.65% |
| iShares Trust-iShares Russell 2000 Value ETF | 31.89K | 0.47% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 25.79K | 0.38% |
| BNY Mellon Investment Funds I-BNY Mellon Small/Mid Cap Growth Fund | 23.89K | 0.35% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 22.27K | 0.33% |
| iShares Trust-iShares Micro-Cap ETF | 14.21K | 0.21% |
Frequently asked questions
Who is the largest shareholder of Monopar Therapeutics?
Janus Henderson Group Ltd. is the largest institutional shareholder of MNPR, owning 16.52% of shares outstanding (1.12M shares) as of its latest 13F filing.
What percentage of Monopar Therapeutics is owned by institutions?
Institutions own about 92.0% of MNPR shares and 119.8% of the public float.
How much of Monopar Therapeutics do insiders own?
Insiders, such as officers and directors, own about 23.24% of MNPR shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.